ImmunityBio, Inc.披露2026年第一季度业绩报告显示，公司单季度产品净收入飙升至4400万美元，较去年同期实现近2.7倍增长，延续了2025财年全年700%的同比营收增长态势。截至季度末，公司现金及有价证券储备规模达到3.81亿美元，为后续研发与商业化布局提供充足资金支持。
本季度业绩突破主要得益于核心产品商业化进程加速，反映出公司在肿瘤免疫治疗领域的市场渗透率持续提升。值得注意的是，此次营收跃升建立在2025财年爆发式增长基础上，表明公司已进入规模化营收阶段。
当前充足的现金储备将为临床试验扩展、生产线建设及全球市场拓展提供战略保障。随着产品管线的持续深化，市场关注点已从技术验证转向商业化落地能力，本期财务数据进一步强化了投资者对该公司成长路径的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.